Frontiers in medicine · 2026
Refractive outcomes following anti-VEGF, vitrectomy, cryotherapy, and laser photocoagulation for retinopathy of prematurity: a systematic review and meta-analysis.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Yu-Te, Wang I-Ming, Wang I-Jong, Shao Yi-Ching, Hsia Ning-Yi, Lin Hui-Ju
Аннотация
BACKGROUND: Retinopathy of prematurity (ROP) survivors commonly develop myopia, yet refractive sequelae may differ substantially by treatment. We compared long term refractive outcomes after anti-VEGF, laser photocoagulation, cryotherapy, and vitrectomy.
METHODS: A systematic review was performed using PubMed, Embase, Web of Science, and the Cochrane Library from inception to July 2025. We also screened records from a curated EndNote library. The primary outcomes were mean spherical equivalent (SE) and the prevalence of high myopia (SE ≤ -5.0 D). Pooled estimates were calculated using a DerSimonian and Laird random effects model. Prespecified subgroup analyses compared treatment zone (Zone I vs. Zone II or III) and monotherapy vs. combination therapy.
RESULTS: Eighty-six studies, including 10,269 eyes were analyzed. Anti-VEGF had the least myopic pooled mean SE (-1.9 D) compared with laser (-3.8 D), cryotherapy (-5.8 D), and vitrectomy (-6.3 D). High myopia prevalence was 21.3% after anti-VEGF versus 42.6% after laser, and 55.4% to 58.6% after vitrectomy or cryotherapy. Compared with laser, anti-VEGF reduced the risk of high myopia (RR = 0.39; 95% CI: 0.25-0.61). Heterogeneity was moderate to high (I2 = 52%-78%), and Egger's tests were not significant (p = 0.21 for SE; p = 0.37 for high myopia).
CONCLUSION: Among major ROP treatments, anti-VEGF was associated with the most favorable refractive outcomes, while cryotherapy and vitrectomy showed the highest myopic burden. These findings support incorporating long term refractive consequences and zone-specific risk into treatment selection and follow up planning.
METHODS: A systematic review was performed using PubMed, Embase, Web of Science, and the Cochrane Library from inception to July 2025. We also screened records from a curated EndNote library. The primary outcomes were mean spherical equivalent (SE) and the prevalence of high myopia (SE ≤ -5.0 D). Pooled estimates were calculated using a DerSimonian and Laird random effects model. Prespecified subgroup analyses compared treatment zone (Zone I vs. Zone II or III) and monotherapy vs. combination therapy.
RESULTS: Eighty-six studies, including 10,269 eyes were analyzed. Anti-VEGF had the least myopic pooled mean SE (-1.9 D) compared with laser (-3.8 D), cryotherapy (-5.8 D), and vitrectomy (-6.3 D). High myopia prevalence was 21.3% after anti-VEGF versus 42.6% after laser, and 55.4% to 58.6% after vitrectomy or cryotherapy. Compared with laser, anti-VEGF reduced the risk of high myopia (RR = 0.39; 95% CI: 0.25-0.61). Heterogeneity was moderate to high (I2 = 52%-78%), and Egger's tests were not significant (p = 0.21 for SE; p = 0.37 for high myopia).
CONCLUSION: Among major ROP treatments, anti-VEGF was associated with the most favorable refractive outcomes, while cryotherapy and vitrectomy showed the highest myopic burden. These findings support incorporating long term refractive consequences and zone-specific risk into treatment selection and follow up planning.